A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Public ClinicalTrials.gov record NCT06013241. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps - The BiRCh Study
Study identification
- NCT ID
- NCT06013241
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Insmed Incorporated
- Industry
- Enrollment
- 288 participants
Conditions and interventions
Conditions
Interventions
- Brensocatib Drug
- Placebo Drug
- Mometasone furoate nasal spray (MFNS) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 29, 2023
- Primary completion
- Sep 29, 2025
- Completion
- Oct 29, 2025
- Last update posted
- Nov 9, 2025
2023 – 2025
United States locations
- U.S. sites
- 27
- U.S. states
- 14
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USA034 | Tucson | Arizona | 85704 | — |
| USA002 | Roseville | California | 95661 | — |
| USA006 | Upland | California | 91786 | — |
| USA016 | Boca Raton | Florida | 33487 | — |
| USA019 | Hollywood | Florida | 33024 | — |
| USA001 | Miami | Florida | 33135 | — |
| USA009 | Tampa | Florida | 33613 | — |
| USA031 | Chicago | Illinois | 60611 | — |
| USA021 | Chicago | Illinois | 60612 | — |
| USA003 | New Albany | Indiana | 47150 | — |
| USA035 | Mandeville | Louisiana | 70471 | — |
| USA026 | Baltimore | Maryland | 21287 | — |
| USA011 | Columbia | Missouri | 65212 | — |
| USA024 | St Louis | Missouri | 63141 | — |
| USA033 | New York | New York | 10016 | — |
| USA028 | Tulsa | Oklahoma | 74132 | — |
| USA004 | Tulsa | Oklahoma | 74136 | — |
| USA015 | Hershey | Pennsylvania | 17033 | — |
| USA023 | Charleston | South Carolina | 29425 | — |
| USA022 | North Charleston | South Carolina | 29406 | — |
| USA025 | Dallas | Texas | 75231 | — |
| USA037 | Fredericksburg | Texas | 78624 | — |
| USA029 | Houston | Texas | 77022 | — |
| USA018 | Houston | Texas | 77030 | — |
| USA030 | San Antonio | Texas | 78258 | — |
| USA038 | Tomball | Texas | 77375 | — |
| USA005 | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06013241, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06013241 live on ClinicalTrials.gov.